REG - Genflow Biosciences - Appointment of Joint Broker

Genflow BiosciencesAnnouncement

08/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231108:nRSH7060Sa&default-theme=true

RNS Number : 7060S  Genflow Biosciences PLC  08 November 2023

 

8 November 2023

 

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Appointment of Joint Broker

 

The Company (LSE:GNF) (OTCQB:GENFF), is pleased to announces today that it
has appointed Capital Plus Partners Ltd to act as Joint Broker, alongside
Clear Capital Markets, with immediate effect.

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

 Genflow Biosciences Plc
 Dr Eric Leire              +32 477 495 881

 Chief Executive Officer

 Clear Capital Markets
 Joint Corporate Broker     +44 203 869 6080

 Bob Roberts

 Capital Plus Partners Ltd
 Joint Corporate Broker

 Dominic Berger             +44 203 821 6167

 

About Genflow Biosciences

 

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

 

Its mission is to increase our understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

 

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPKZMGMRNRGFZM